

Pourseif MM., et al., *BiolImpacts*, 2019, 9(3), 131-144

doi: [10.15171/bi.2019.18](https://doi.org/10.15171/bi.2019.18)

<http://bi.tbzmed.ac.ir/>

## **A multi-method and structure-based in silico vaccine designing against *Echinococcus granulosus* through investigating enolase protein**

**Mohammad Mostafa Pourseif<sup>1,2</sup>, Mitra Yousefpour<sup>1\*</sup>, Mohammad Aminianfar<sup>2</sup>, Gholamali Moghaddam<sup>3</sup>, Ahmad Nematollahi<sup>4</sup>**


<sup>1</sup> Department of Physiology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran

<sup>2</sup> Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Department of Aerospace and Subaquatic Medicine, AJA University of Medical Sciences, Tehran, Iran


<sup>3</sup> Department of Animal Sciences, Faculty of Agriculture, University of Tabriz, Tabriz, Iran

<sup>4</sup> Department of Pathobiology, Veterinary College, University of Tabriz, Tabriz, Iran


-----




**Fig. S1.** The plots show the sequence-based prediction of potential transmembrane topology and signal peptide in the EgEnolase protein sequence. **(A)** The prediction plot shows subcellular localization of EgEnolase protein by using the TMHMM server. **(B)** Transmembrane topology profile of EgEnolase protein obtained from TMPred server. **(C)** The potential transmembrane helix of EgEnolase protein predicted in the TOPCONS server and based on six different algorithms. **(D)** The consensus prediction plot of TOPCONS server.



**Fig. S2.** Prediction of the post-translational modifications in the EgEnolase protein sequence. **(A)** The plot indicates the residue (17-NPT-20) with the potential N-glycosylation site. **(B)** Serine, Threonine, and Tyrosine phosphorylation plot obtained from the NetPhos v2.0 web-server. The scores more than the threshold value (0.5) were predicted as a phosphorylation site.



**Fig. S3.** Solvent accessible and hydrophobic regions of the EgEnolase protein sequence. **(A)** The plot illustrates surface-accessible regions of the EgEnolase protein sequence. **(B)** The hydrophobic residues are shown as plot and based on the Kyte and Doolittle algorithm. The negative values are related to the hydrophilic amino acids.



**Fig. S4.** ProSA-based energy plots for the 3D models. The energy plot for EgEnolase (A), DRB1\*01101 (B), *C. lupus* Toll-like receptor

2 (C), and *C. lupus* Toll-like receptor 4 (D) are represented. The negative values of the plots are related to the stable residues.

beta-enolase isoform X1 [Canis lupus familiaris]

Sequence ID: [XP\\_536606.4](#) Length: 440 Number of Matches: 5

[▶ See 1 more title\(s\)](#)

Range 1: 26 to 143 [GenPept](#) [Graphics](#)

▼ Next Match ▲ Previous Match

Score	Expect	Method	Identities	Positives	Gaps
77.4 bits(189)	2e-14	Compositional matrix adjust.	43/118(35%)	66/118(55%)	15/118(12%)
Query 421	VKIGMDVAFFRKGPSLPSGASTGVHEAVELRDADKNAYMGKGG-----GGSGGGGSIK				473
	V++ + A R ++PSGAST ++EA+ELRD DK+ Y+GKG + G ++				
Sbjct 26	VEVDLHTAKGRFRAAVPSGASTLIYEALERDGDKSRYLKGGVVKAVEHINKTLGPALLE				85
Query 474	EKFVVDQQRIDEFMIKLDGSPNKGKLGSGGGGGSG-----GGGSMGTEVYHHLKSV				523
	+K V DQ+++D+FMI+LDG+ NK K G G G G +Y H+ +				
Sbjct 86	KKLSVVDQEKVDFMIELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPLYRHIADL				143

**Fig. S5.** The alignment output between the vaccine protein sequence and the most similar protein based on the NCBI's blastp (protein-protein BLAST) algorithm. The similar proteins were searched among *Canis lupus familiaris* proteome information.

**(A)**

```

IFIIVVLINATTQYDCVTSSEVVSDSYNKTTITFENKPQYNSPSGNVVPKAIMPIIKKGQTIQVSSITNVKYEATNQD
LTFLFRKDGCHGTNSEIATYAGATNTNVFLGNTNTVSLTQFKFTADYNGIILVGNKLGASLPGDIRVNVFEAAAKEAA
AKAPPHALSEAAAKLAMQEFMILPTGFFRKGPGGALIIHARQIFDSFFRKGPGGAMQEFMILPTGAKFFRKG
GPGGEFMILPTGAKSFSFFRKGPGGLIIHARQIFDSRFFRKGPGGMSRAAGWGMVMSHFFRKGPGGAGWGM
VSHRSGEFFRKGPGGLRIEEELGPKAVYFFRKGPGGKAVYAGEHFRNPLFFRKGPGGYPIVSIEDPFDQDFFRKG
GPGGVLPVPSFVNLNGGFFRKGPGGGYTGKVKIGMDVAFFRKGPSLPSGASTGVHEAVELRDADKNAYMGKG
GGSGGGGSIKEKFFVTDQQRIDEFMIKLDGSPNKGKLGGGGSGGGGSMGTEVYHHLKSVIKGKYLDACNVG
GGSGGGGSKTAIDKAGYTGKVKGGGSGGGGSEFYQDGNYNLDFKNPKAAASSIVSGKLSDI
  
```

Adjuvants: IFIIV...NVF and APPHALS  
 Linkers: <sup>E</sup>AAAK, <sup>F</sup>FRK, <sup>G</sup>PGPG, <sup>G</sup>PSL, and <sup>G</sup>GGSGGGG  
 Helper T-cell Epitope: 13-mer epitopes

**(B)**

```

ATTTTTATTATTGTGGTGTGATTAACCGCACCACCAGTATGATTGCGTGACCAGCAGCGAAGTGGT
GAGCGATAGCTATAACAAAACCACCTTACCTTTGAAAACAACCCGAGTATTATAACAGCCCGAGCG
GCAACGTGGTGGCGAAAGCGATTATGCCGATCTGATTAAAAAAGGCCAGACCAATTCAAGTGAGCAGC
ATTACCGACCAACGTGAAATATGAAGCGACCAACCCAGGATCTGACCTTTCTGTTTGGCAAAGATGGCTG
CCATGGCACCAACAGCGAAATATGCGACCTATGCGGGCCGACCAACCAACCGTCTTCTGGGGAAACA
CCAACACCGTGAGCTGACCCAGTTTAAATTTACCGCGGATTATAACGGCATTATTCTGATTGTGGCC
AAAACTGGGGCCGAGCTGCGGGGATATTGCGTGAACGTGTITGAAAGCGCCGCGAAAGAAAGC
GGCGCGAAAGCCCGCGCATGCGCTGAGCGAAGCGGGCGGCAAAAACTGGCGATGCAGGAATTTA
TGATTCGCCACCGCTTTTTCGCAAAGCCCGGGCCGCGCGCTGATTCATCGCGCC
AGATTTTGATAGCTTTTTCGCAAAGCCCGGGCCGCGCGATGCAAGAAATTATGATTCGCGC
ACCGGGCGAAATTTTTGCAAAGCCCGGGCCGCGCGAATTTATGATTCGCCACCGCGCGAA
AAGCTTAGCTTTTTGCAAAGCCCGGGCCGCGCGCTGATTTATCATGGCGCCAGATTTTGATA
GCGCTTTTTGCAAAGCCCGGGCCGCGCGCATGAGCGCGCGGGCTGCGGCTGATGGTAGCCATGCGAGCGCGAA
TTTTTTGCAAAGCCCGGGCCGCGCGCTGCGGATTGAAGAAGAACTGGCGCAAGCGGTGATTTT
TCGCAAAGCCCGGGCCGCGCGTATCCGATTGTGAGCATTGAAGATCCGTTTATCAGGATTTTTTC
GCAAAGCCCGGGCCGCGCGTGTGCGGTGCGAGCTTTAAGTGCCTGAACCGCGGCTTTTTTCGCA
AAGCCCGGGCCGCGCGCTATACCGCAAAGTAAAAATTGGCATGGATGTGGCTTTTTTCGCAA
GGCCCGAGCTGCGAGCGGGCGGAGCACCGCGCTGCATGAAGCGTGAACCTGCCGATGCGGATAA
AAGCGCTATATGGCAAAGCCCGGGCCGCGCGAGCGCGCGCGCGCAGCAATTAAGAAAATTTGTGG
TGACCGATCAGCAGCGCATGATGAATTTATCATTAACTGGATGGCAGCCCGAAACAAAGGCAAACTG
GGCGGGCGGGCCGAGCGCGCGCGGCGAGCGACCGCAAGGTATCATCATCGAAAGCGT
GATTAAGGCAAAATAGCCCTGGATGCGTGAACGCTGGGGCGGGCGCAGCGGGCGGGCGGCA
AAACCGGATTTGATAAAGCGGCTATACCGCAAAGTGAAGCGCGGGCGCAGCGGGCGGGCG
AGCAGCAATTTTATCAGGATGGCAACTATAACCTGGATTTTAAAAACCCGAAAGCGCGCGAGCAG
CATGTGAGCGCAGCAAACTGAGCGATTTTAA
  
```

**Fig. S6.** The primary sequence of the designed multi-epitope vaccine. Amino acid sequence (A), and nucleotide sequence (B) of the

vaccine construct.

**Table S1.** Antigenic scores for eight EgEnolase protein sequences in terms of two different predictor tools.



NCBI accession number	Prediction method	
	ANTIGENpro	VaxiJen v2.0
ACY30465	0.5309	0.4814
XP_024346720	0.4791	0.3705
EUB55526	0.3309	0.2935
XP_024346722	0.3309	0.2935
EUB55524	0.4791	0.3705
CDS19796	0.5903	0.4814
CDS21390	0.4791	0.3705

**Table S2.** The six high rank homologous PDB structures that were used as template for homology modeling.

<b>Query proteins</b>	<b>PDB Templates</b>	<b>Identity (%)</b>	<b>Total score</b>
<b>TLR-2</b>	2Z7X	75	768
	5D3I	64	744
	3A79	59	657
	2Z81	61	645
	2Z80	70	403
	1O77	90	284
<b>TLR-4</b>	4G8A	68	795
	3FXI	68	791
	3VQ1	59	696
	2Z64	59	692
	2Z63	67	672
	5IJB	55	605
	2PSN	75	682

<b>EgEnolase</b>	3B97	75	679
	2XSX	73	670
	4ZA0	72	658
	1TE6	71	655
	3UCC	71	655
<hr/>			
<b>DRB1*01101</b>	4AH2	82	74
	3PDO	82	74
	1AQD	82	74
	4X5X	81	74
	2WBJ	79	74
	1YMM	80	74
<hr/>			

**Table S3.** Binding energy between eighty 13-mer peptides and DLA-DRB1\*01101 allele obtained from the molecular docking method.

13-mer peptides	weighted score <sup>¶</sup>		13-mer peptides	weighted score		13-mer peptides	weighted score	
	center	lowest E		center	lowest E		center	lowest E
GALIIHARQIFDS	-825.7	-999.1	GVSLAVCKAGAAE	-602.3	-633.7	SSIVSGSKLSDIY	-626.0	-685.1
LIIHARQIFDSR	-793.3	-945.2	CKAGAAEKGVPPLY	-587.5	-670.3	SKLSDIYSEMISK	-603.1	-678.8
HARQIFDSRGNPT	-616.4	-809.5	AEKGVPLYRHVAD	-623.5	-711.1	YSEMISKYPIVSI	-675.1	-819.4
ARQIFDSRGNPTV	-580.5	-721.6	PLYRHVADLAGNK	-605.8	-746.5	YPIVSIEDPFDQD	-876.3	-896.0
FDSRGNPTVEVDL	-786.6	-786.6	VADLAGNKDVVLP	-571.3	-675.7	DPFDQDDWAAWTE	-762.9	-821.4
DSRGNPTVEVDLT	-691.1	-711.3	GNKDVVLPVPSFN	-708.8	-830.6	DWAAWTEFNAKAG	-718.3	-805.3
NPTVEVDLTTSKG	-676.0	-712.7	VLPVPSFNVLNGG	-844.0	-896.6	FNAKAGIQIVGDD	-623.8	-769.6
VEVDLTTSKGLFR	-748.5	-763.1	FNVLNGGSHAGNK	-635.1	-727.1	IQIVGDDLTVTNP	-652.9	-812.7
DLTTSKGLFRAAV	-634.1	-710.4	GSHAGNKLAMQEF	-613.0	-702.8	LTVTNPERVQQAI	-611.1	-678.6
TSKGLFRAAVPSG	-675.9	-812.7	KLAMQEFMILPTG	-906.4	-1016.2	RVQQAIDRKACNA	-604.3	-667.7
LFRAAVPSGASTG	-750.5	-848.3	AMQEFMILPTGAK	-882.7	-983.0	DRKACNALLLKVN	-684.5	-815.0
AVPSGASTGVHEA	-574.4	-713.7	EFMILPTGAKSFS	-801.7	-946.9	ALLLKVNQIGSVT	-716.3	-719.2
ASTGVHEAVELRD	-627.7	-813.8	TGAKSFSEAMKMG	-581.1	-736.1	IGSVTESIKACKM	-687.7	-687.7
VHEAVELRDADKN	-720.5	-770.4	FSEAMKMGTEVYH	-673.6	-730.0	KACKMSRAAGWGV	-658.5	-746.5
VELRDADKNAYMG	-636.3	-747.7	MKMGTEVYHHLKS	-715.1	-715.1	MSRAAGWGMVSH	-922.9	-922.9
DADKNAYMGKGV	-595.1	-712.6	GTEVYHHLKSVIK	-528.5	-638.2	AGWGMVSHRSGE	-819.7	-916.8
NAYMGKGVNAVK	-594.5	-664.3	LKSVIKGKYGLDA	-720.3	-773.5	VSHRSGETEDSTI	-618.1	-729.4
GKGVNAVKNVNE	-499.4	-556.7	GKYGLDACNVGDE	-669.4	-858.5	ETEDSTIADIVVG	-554.9	-632.4
LVNAVKNVNEVIAP	-505.6	-597.1	LDACNVGDEGGFA	-746.1	-813.1	STIADIVVGLRTG	-603.1	-703.3
KNVNEVIAPALIK	-569.6	-578.6	GDEGGFAPNIQDN	-626.0	-712.3	IADIVVGLRTGQI	-669.7	-794.5

EVIAPALIKEKFV	-743.7	-804.9	APNIQDNMEGLEL	-579.1	-645.3	GLRTGQIKTGAPC	-738.8	-833.7
ALIKEKFVVTDQQ	-687.0	-823.2	NMEGLELLKTAID	-513.2	-619.5	IKTGAPCRSERLA	-656.9	-711.1
VVTDQQRIDEFMI	-709.4	-774.6	LKTAIDKAGYTGK	-723.0	-776.9	CRSERLAKYNQLL	-715.0	-756.8
QQRIDEFMIKLDG	-635.2	-779.2	GYTGKVKIGMDVA	-859.7	-859.7	SERLAKYNQLLRI	-639.9	-716.5
EFMIKLDGSPNKG	-578.3	-634.6	KIGMDVAASEFYQ	-612.2	-773.3	AKYNQLLRIEEEEL	-629.2	-702.1
DGSPNKGKLGANA	-365.8	-470.3	ASEFYQDGNYNLD	-626.6	-743.8	LRIEEEELGPKAVY	-710.7	-909.9
KGKLGANAILGVS	-463.4	-592.5	FYQDGNYNLDFKN	-778.0	-778.6	LGPKAVYAGEHFR	-792.8	-885.1
ANAILGVSLAVCK	-601.5	-665.7	KNPKAAASSIVSG	-490.5	-555.1	KAVYAGEHFRNPL	-743.9	-903.3

---

<sup>†</sup> binding energy unit is kJ/mol. \*The lowest binding energy value between the 13-mer peptides of EgEnolase and DRB1\*01101 allele was selected as final CD4<sup>+</sup> T-helper epitope.